Dergiler / Marmara Medical Journal / 2021 / Cilt: 34 - Sayı: 2

Determination of fosfomycin susceptibility in carbapenemaseproducing K. pneumoniae strains isolated prior to clinical use of the intravenous formulation in Turkey

Sayfa
127–131
Yayın Tarihi
2021-05-31
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusions: Although, the susceptibility of fosfomycin, which has just been put into the clinical use of intravenous formulation in Turkey, is not very high, it can be considered as an alternative

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: The incidence of infections caused by carbapenem-resistant Enterobacteriaceae has increased worldwide.
📊
Temel Bulgular & Veri:Materials and Methods: A total of the 155 K. pneumoniae isolates which previously characterized at the molecular level for their carbapenemase were included in this study.
💡
Sonuç & Katkı:Conclusions: Although, the susceptibility of fosfomycin, which has just been put into the clinical use of intravenous formulation in Turkey, is not very high, it can be considered as an alternative
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Fosfomycin susceptibility · Carbapenemase-producing · Klebsiella pneumoniae

Abstract

Objectives: The incidence of infections caused by carbapenem-resistant Enterobacteriaceae has increased worldwide. Limitations in the development of new antimicrobial agents have led clinicians to reconsider the clinical efficiency of old antibiotics, such as intravenous formulation of fosfomycin, in the treatment of multidrug-resistant Gram-negative bacterial infections. We investigated the fosfomycin susceptibility of carbapenemase-producing Klebsiella pneumoniae strains isolated prior to the clinical use of the intravenous formulation of fosfomycin in Turkey. Materials and Methods: A total of the 155 K. pneumoniae isolates which previously characterized at the molecular level for their carbapenemase were included in this study. The minimum inhibitory concentration of fosfomycin was determined by the agar dilution method. Results: Overall, 65.1% of the isolates were susceptible to fosfomycin. The MIC50 and MIC90 values were 32 and 256 mg/L, respectively. According to our results, at least two-third of carbapenemase-positive K. pneumoniae are susceptible to fosfomycin. Conclusions: Although, the susceptibility of fosfomycin, which has just been put into the clinical use of intravenous formulation in Turkey, is not very high, it can be considered as an alternative

🔖

Bu Makaleye Atıf Yap

GELMEZ, G. A., CAN, B., SENGEL, B. E., KORTEN, V., SOYLETIR, G. (2021). Determination of fosfomycin susceptibility in carbapenemaseproducing K. pneumoniae strains isolated prior to clinical use of the intravenous formulation in Turkey. Marmara Medical Journal, Cilt: 34 - Sayı: 2, 127–131. https://ajindex.com/articles/688312

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (5)

  1. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 2012; 25:682–707. doi: 10.1128/CMR.05035-11
  2. Queenan AM, Bush K. Carbapenemases: the versatile betalactamases. Clin Microbiol Rev 2007; 20(3):440–458. doi: 10.1128/CMR.00001-07 Walsh TR. Emerging carbapenemases: a global perspective. Int J Antimicrob Agents 2010; 36 Suppl 3: 8–14. doi: 10.1016/ S0924-8579(10)70004-2
  3. Sheu CC, Chang YT, Lin SY, Chen YH, Hsueh PR. Infections caused by carbapenem-resistant Enterobacteriaceae: An update on therapeutic options. Front Microbiol 2019; 10:80. doi: 10.3389/fmicb.2019.00080 Raz R. Fosfomycin: an old-new antibiotic. Clin Microbiol Infect 2012;18(1):4–7. doi: 10.1111/j.1469-0691.2011.03636.x Grabein B, Graninger W, Rodríguez Baño J, et al. Intravenous fosfomycin–back to the future. Systemic review and metaanalysis of the clinical literature. Clin Microbiol Infect 2017; 23(6): 363–372. doi: 10.1016/j.cmi.2016.12.005 Michalopoulos A, Virtzili S, Rafailidis P, et al. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect 2010; 16(2):184–186. doi: 10.1111/j.1469-0691.2009.02921.x European Committee on Antimicrobial Susceptibility Testing (EUCAST): Clinical breakpoints version 9.0. In: European Committee on Antimicrobial Susceptibility Testing. Vaxjo: EUCAST 2019. Available from: http://www.eucast.org
  4. Aktaş Z, Kayacan CB, Schneider I, et al. Carbapenem hydrolyzing oxacillinase, OXA-48, persists in Klebsiella pneumoniae in Istanbul, Turkey. Chemotherapy 2018; 54(2):101–106. doi: 10.1159/000118661. Perry JD, Naqvi SH, Mirza IA, et al. Prevalence of faecal carriage of Enterobacteriaceae with NDM-1 carbapenemase at military hospitals in Pakistan, and evaluation of two chromogenic media. J Antimicrob Chemother 2011; 66(10):2288–2294. doi: 10.1093/jac/dkr299 Pitout JD, Gregson DB, Poirel L, et al. Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory. J Clin Microbiol 2005; 43(7):3129–35. doi: 10.1128/JCM.43.7.3129-3135.2005.
  5. Cole JM, Schuetz AN, Hill CE, Nolte FS. Development and evaluation of a real-time PCR assay for detection of Klebsiella pneumoniae carbapenemase genes. J Clin Microbiol 2009; 47(2):322–326. doi: 10.1128/JCM.01550-08 Roussos N